These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

951 related articles for article (PubMed ID: 27429374)

  • 1. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Cheng CK; Chang CK; Peng CH
    Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
    Smretschnig E; Ansari-Shahrezaei S; Hagen S; Glittenberg C; Krebs I; Binder S
    Retina; 2013 Feb; 33(2):316-23. PubMed ID: 23314238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy.
    Nicolò M; Zoli D; Musolino M; Traverso CE
    Am J Ophthalmol; 2012 Mar; 153(3):474-480.e1. PubMed ID: 22019224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy.
    Nicoló M; Eandi CM; Alovisi C; Grignolo FM; Traverso CE; Musetti D; Cardillo Piccolino F
    Am J Ophthalmol; 2014 May; 157(5):1033-7. PubMed ID: 24487046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol.
    Breukink MB; Mohr JK; Ossewaarde-van Norel A; den Hollander AI; Keunen JE; Hoyng CB; Boon CJ
    Acta Ophthalmol; 2016 Mar; 94(2):187-97. PubMed ID: 26670630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 50% vs 30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial.
    Zhao M; Zhang F; Chen Y; Dai H; Qu J; Dong C; Kang X; Liu Y; Yang L; Li Y; Zhou P; Pan CT; Zhang L; Liu P; Zhou H; Jiao X; Xiong Y; Tian R; Lu Y; Yu X; Li X
    JAMA Ophthalmol; 2015 Mar; 133(3):333-40. PubMed ID: 25555191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial.
    Chan WM; Lai TY; Lai RY; Liu DT; Lam DS
    Ophthalmology; 2008 Oct; 115(10):1756-65. PubMed ID: 18538401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial.
    Bae SH; Heo J; Kim C; Kim TW; Shin JY; Lee JY; Song SJ; Park TK; Moon SW; Chung H
    Ophthalmology; 2014 Feb; 121(2):558-65. PubMed ID: 24268858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.
    Fujita K; Imamura Y; Shinoda K; Matsumoto CS; Mizutani Y; Hashizume K; Mizota A; Yuzawa M
    Ophthalmology; 2015 Mar; 122(3):555-61. PubMed ID: 25444637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial.
    Reibaldi M; Cardascia N; Longo A; Furino C; Avitabile T; Faro S; Sanfilippo M; Russo A; Uva MG; Munno F; Cannemi V; Zagari M; Boscia F
    Am J Ophthalmol; 2010 Feb; 149(2):307-315.e2. PubMed ID: 19896635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Observation on long-term efficacy of half-dose photodynamic therapy with chronic central serous chorioretinopathy using optical coherence tomography].
    Liu Y; Li L; Xu G; Wang W
    Zhonghua Yan Ke Za Zhi; 2016 May; 52(5):328-34. PubMed ID: 27220704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy.
    Maruko I; Iida T; Sugano Y; Ojima A; Ogasawara M; Spaide RF
    Ophthalmology; 2010 Sep; 117(9):1792-9. PubMed ID: 20472289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of visual and anatomical outcomes of half-fluence and half-dose photodynamic therapy in eyes with chronic central serous chorioretinopathy.
    Kim YK; Ryoo NK; Woo SJ; Park KH
    Graefes Arch Clin Exp Ophthalmol; 2015 Dec; 253(12):2063-73. PubMed ID: 25616728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional retinal changes measured by microperimetry in standard-fluence vs low-fluence photodynamic therapy in chronic central serous chorioretinopathy.
    Reibaldi M; Boscia F; Avitabile T; Uva MG; Russo A; Zagari M; Occhipinti F; Russo V; Reibaldi A; Longo A
    Am J Ophthalmol; 2011 Jun; 151(6):953-960.e2. PubMed ID: 21457929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy.
    Bae SH; Heo JW; Kim C; Kim TW; Lee JY; Song SJ; Park TK; Moon SW; Chung H
    Am J Ophthalmol; 2011 Nov; 152(5):784-92.e2. PubMed ID: 21742303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
    Matušková V; Vysloužilová D; Uher M
    Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of half-fluence photodynamic therapy depending on the degree of choroidal hyperpermeability in chronic central serous chorioretinopathy.
    Lim SH; Chang W; Sagong M
    Eye (Lond); 2013 Mar; 27(3):353-62. PubMed ID: 23449515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retinal sensitivity after photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy: short-term results.
    Fujita K; Yuzawa M; Mori R
    Retina; 2011 Apr; 31(4):772-8. PubMed ID: 20890236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.
    Sheptulin V; Purtskhvanidze K; Roider J
    Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2027-2034. PubMed ID: 30097783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microperimetric changes and fixation stability status after half-dose photodynamic therapy for chronic central serous chorioretinopathy.
    Gulkas S; Sahin O
    Eur J Ophthalmol; 2020 Sep; 30(5):1053-1060. PubMed ID: 31256613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.